• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Video

The Race to Cure Alzheimer's is On: These Are the Forerunners

Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
By ARI FIMA
Jul 26, 2018 | 04:03 PM EDT
Stocks quotes in this article: ESALY, AZN, LLY, PFE, BIIB

Top pharmaceutical companies like Alzheon and Biogen  (BIIB) , shares of which plummeted in late afternoon trading on Thursday, are working to discover a cure for Alzheimer's.

The neurodegenerative disease currently affects over 45 million people worldwide, according to the World Alzheimer Report.

"It's an incredibly tough puzzle to crack," says P. Murali Doraiswamy, the head of biological psychiatry at Duke University. "I think a form of cure is more likely to come from delaying the onset rather than by growing new brain cells to repair lost tissue."

BAN2401, which is being developed by Biogen and Eisai Co. Ltd. (ESALY) , has been shown to reduce the rate of cognitive decline in patients with the neurodegenerative disease by 30 percent at the highest dose compared to placebo over an 18-month period, which exceeded analysts' expectations of a 15-20% reduction.

The drug showed statistically significant improvement across a few composite measures, including the Alzheimer's Disease Assessment Scale-cognitive sub scale, where it showed a 47% reduction in cognitive decline. BAN2401 was also shown to reduce the amount of amyloid plaque buildup by 93%.

Biogen is also working on another medication called Aducanumab, but results won't be out until 2020.

BAN2401 and Aducanumab are both antibodies that latch onto and reduce the amount of amyloid plaques that build up in the brain. Amyloid plaque buildup is currently the prevailing theory for the cause of Alzheimer's, and strong results could support the continuation of investigative studies based on the beta-amyloid hypothesis, analysts say.

Both Eli Lily (LLY) and AstraZeneca (AZN) have discontinued late-stage trials of their Alzheimer's drug, Lanabecestat.

Pfizer (PFE) also dropped its search for an Alzheimer's cure earlier this year.

 

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

TAGS: Investing | Markets | Healthcare | Pharmaceuticals | Video |

More from Video

Amid the Selling, Here's the Big Question Now

James "Rev Shark" DePorre
Feb 25, 2021 4:43 PM EST

How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.

One Tweet Pulls the Rug Out From Under the Indexes

James "Rev Shark" DePorre
Oct 6, 2020 4:44 PM EDT

Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.

A Technical Look at the New Dow Jones Industrial Average

Bruce Kamich
Aug 25, 2020 1:11 PM EDT

Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.

Conagra Brands Looks Tastier After Its Upgrade to Buy

Bruce Kamich
Dec 30, 2019 12:39 PM EST

CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.

Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts

Bruce Kamich
Oct 30, 2019 1:13 PM EDT

Breaking down an approach to the long side of this biotech stock.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:51 PM EDT PAUL PRICE

    We Should Be in for Better Starting Soon

    Window dressing Thursday, the last day of the...
  • 11:56 AM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    Check out what's going on in the Stocks Under $10 ...
  • 12:04 AM EDT PAUL PRICE

    Two Good Signs -- Especially for Small-Cap Investors

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login